Allott, Emma H.
Geradts, Joseph
Cohen, Stephanie M.
Khoury, Thaer
Zirpoli, Gary R.
Bshara, Wiam
Davis, Warren
Omilian, Angela
Nair, Priya
Ondracek, Rochelle P.
Cheng, Ting-Yuan David
Miller, C. Ryan
Hwang, Helena
Thorne, Leigh B.
O’Connor, Siobhan
Bethea, Traci N.
Bell, Mary E.
Hu, Zhiyuan
Li, Yan
Kirk, Erin L.
Sun, Xuezheng
Ruiz-Narvaez, Edward A.
Perou, Charles M.
Palmer, Julie R.
Olshan, Andrew F.
Ambrosone, Christine B.
Troester, Melissa A.
Funding for this research was provided by:
National Institutes of Health (CA151135, CA058420, CA164974, CA098663, CA100598, CA185623, CA58223, CA179715, CA016086)
Susan G. Komen
Breast Cancer Research Foundation
American Institute for Cancer Research
University Cancer Research Fund of North Carolina
Article History
Received: 28 August 2017
Accepted: 25 January 2018
First Online: 6 February 2018
Ethics approval and consent to participate
: Each study contributing to the AMBER consortium was approved by the individual Institutional Review Boards at participating hospitals and academic institutions, and written informed consent was obtained from each study participant. The CBCS was approved by the Institutional Review Board at the University of North Carolina at Chapel Hill School of Medicine. The BWHS was approved by the Institutional Review Board at the Boston University School of Medicine. The WCHS was approved by the Institutional Review Boards at the University of Medicine and Dentistry of New Jersey (presently Rutgers University), Mount Sinai School of Medicine, and Roswell Park Cancer Institute.
: Not applicable
: C. M. Perou is a consultant, an equity stock holder and Board of Director Member of BioClassifier LLC. C. M. Perou is also listed as an inventor on a patent application on the PAM50 molecular assay. None of the other authors declare any conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.